Using competitive binding assays on PC-3 (Prostate cancer cell line GRPR+) cells and LNCaP membranes (Prostate cancer cell line PSMA+), this compound showed strong and high binding affinity to their respective targets. The gene discussed is FOLH1; the disease is prostate carcinoma.